Technical Analysis for NUVL - Nuvalent, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| 50 DMA Resistance | Bearish | -5.24% | |
| 20 DMA Support | Bullish | -5.24% | |
| Bollinger Band Squeeze | Range Contraction | -5.24% | |
| NR7 | Range Contraction | -5.24% | |
| Multiple of Ten Bearish | Other | -5.24% | |
| BB Squeeze Started | Range Contraction | -5.24% | |
| Inside Day | Range Contraction | -5.24% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 5% | about 13 hours ago |
| Down 3% | about 14 hours ago |
| 60 Minute Opening Range Breakdown | about 14 hours ago |
| Fell Below Previous Day's Low | about 15 hours ago |
| Down 2 % | about 15 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 03/28/2023
Nuvalent, Inc. Description
Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Organic Compounds Chemical Compounds Tyrosine Kinase Receptors Preclinical Stage Biopharmaceutical Therapies For Patients With Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 40.43 |
| 52 Week Low | 7.09 |
| Average Volume | 202,546 |
| 200-Day Moving Average | 23.37 |
| 50-Day Moving Average | 30.11 |
| 20-Day Moving Average | 29.19 |
| 10-Day Moving Average | 28.75 |
| Average True Range | 1.95 |
| RSI | 44.44 |
| ADX | 14.07 |
| +DI | 16.75 |
| -DI | 25.59 |
| Chandelier Exit (Long, 3 ATRs) | 27.22 |
| Chandelier Exit (Short, 3 ATRs) | 31.36 |
| Upper Bollinger Bands | 31.43 |
| Lower Bollinger Band | 26.95 |
| Percent B (%b) | 0.21 |
| BandWidth | 15.36 |
| MACD Line | -0.28 |
| MACD Signal Line | -0.31 |
| MACD Histogram | 0.0344 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 30.06 | ||||
| Resistance 3 (R3) | 30.29 | 29.79 | 29.70 | ||
| Resistance 2 (R2) | 29.79 | 29.23 | 29.68 | 29.57 | |
| Resistance 1 (R1) | 28.83 | 28.89 | 28.58 | 28.60 | 29.45 |
| Pivot Point | 28.33 | 28.33 | 28.21 | 28.22 | 28.33 |
| Support 1 (S1) | 27.37 | 27.77 | 27.12 | 27.14 | 26.29 |
| Support 2 (S2) | 26.87 | 27.43 | 26.76 | 26.17 | |
| Support 3 (S3) | 25.91 | 26.87 | 26.05 | ||
| Support 4 (S4) | 25.68 |
